Cargando…

Phenotypic, Genomic and Functional Characterization Reveals No Differences between CD138(++) and CD138(low) Subpopulations in Multiple Myeloma Cell Lines

Despite recent advances in the treatment of multiple myeloma (MM), it remains an incurable disease potentially due to the presence of resistant myeloma cancer stem cells (MM-CSC). Although the presence of clonogenic cells in MM was described three decades ago, the phenotype of MM-CSC is still contro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Paíno, Teresa, Sarasquete, María E., Paiva, Bruno, Krzeminski, Patryk, San-Segundo, Laura, Corchete, Luis A., Redondo, Alba, Garayoa, Mercedes, García-Sanz, Ramón, Gutiérrez, Norma C., Ocio, Enrique M., San-Miguel, Jesús F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3962421/ https://www.ncbi.nlm.nih.gov/pubmed/24658332 http://dx.doi.org/10.1371/journal.pone.0092378

Ejemplares similares

A novel nano-immunoassay method for quantification of proteins from CD138-purified myeloma cells: biological and clinical utility
por: Misiewicz-Krzeminska, Irena, et al.
Publicado: (2018)

Protein Translation Inhibition is Involved in the Activity of the Pan-PIM Kinase Inhibitor PIM447 in Combination with Pomalidomide-Dexamethasone in Multiple Myeloma
por: Paíno, Teresa, et al.
Publicado: (2020)

Isolation of Human CD138(+) Microparticles from the Plasma of Patients with Multiple Myeloma()
por: Krishnan, Sabna Rajeev, et al.
Publicado: (2016)

Syndecan-1 (CD138), Carcinomas and EMT
por: Couchman, John R.
Publicado: (2021)

In vivo evaluation of CD38 and CD138 as targets for nanoparticle-based drug delivery in multiple myeloma
por: Omstead, David T., et al.
Publicado: (2020)

Cardiovascular Involvement of a CD138-Negative Anaplastic Myeloma: A Diagnostic Dilemma
por: Choudhuri, Jui, et al.
Publicado: (2023)

Biological Background of Resistance to Current Standards of Care in Multiple Myeloma
por: Mogollón, Pedro, et al.
Publicado: (2019)

Safety and efficacy of targeting CD138 with a chimeric antigen receptor for the treatment of multiple myeloma
por: Sun, Chuang, et al.
Publicado: (2019)

Loss of Heterozygosity in the Circulating Tumor DNA and CD138+ Bone Marrow Cells in Multiple Myeloma
por: Soloveva, Maiia, et al.
Publicado: (2023)

Soluble syndecan-1 (CD138): is it useful as a prognostic factor in Korean patients with multiple myeloma?
por: Lee, Je-Jung
Publicado: (2010)

The kinesin spindle protein inhibitor filanesib enhances the activity of pomalidomide and dexamethasone in multiple myeloma
por: Hernández-García, Susana, et al.
Publicado: (2017)

Role of CD138, CD56, and light chain immunohistochemistry in suspected and diagnosed plasma cell myeloma: A prospective study
por: Dass, Jasmita, et al.
Publicado: (2019)

Paragraph 138
por: Lippe, Ad.
Publicado: (1887)

Comparison of the IHC Markers CD138 and CD43 in Oral Leukoplakia: An Original Research
por: Akkaloori, Anitha, et al.
Publicado: (2023)

Bone Marrow Mesenchymal Stromal Cells in Multiple Myeloma: Their Role as Active Contributors to Myeloma Progression
por: Maiso, Patricia, et al.
Publicado: (2021)

DEPTOR maintains plasma cell differentiation and favorably affects prognosis in multiple myeloma
por: Quwaider, Dalia, et al.
Publicado: (2017)

Simplified flow cytometric immunophenotyping panel for multiple myeloma, CD56/CD19/CD138(CD38)/CD45, to differentiate neoplastic myeloma cells from reactive plasma cells
por: Jeong, Tae-Dong, et al.
Publicado: (2012)

Expression analysis of multiple myeloma CD138 negative progenitor cells using single molecule microarray readout
por: Jacak, Jaroslaw, et al.
Publicado: (2013)

Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide
por: KAWANO, YAWARA, et al.
Publicado: (2012)

Hypoxia reduces CD138 expression and induces an immature and stem cell-like transcriptional program in myeloma cells
por: KAWANO, YAWARA, et al.
Publicado: (2013)

Validation of interphase fluorescence in situ hybridization (iFISH) for multiple myeloma using CD138 positive cells
por: Kishimoto, Renata Kiyomi, et al.
Publicado: (2016)

Comment on: “Validation of interphase fluorescence in situ hybridization (iFISH) of CD138 positive cells in multiple myeloma”()
por: Zalcberg Renault, Ilana
Publicado: (2016)

Stroma-Mediated Resistance to S63845 and Venetoclax through MCL-1 and BCL-2 Expression Changes Induced by miR-193b-3p and miR-21-5p Dysregulation in Multiple Myeloma
por: Algarín, Esperanza M., et al.
Publicado: (2021)

CD10 and CD138 can be expressed in giant cell tumor of bone: An immunohistochemical study
por: Al-Abbadi, Mousa A., et al.
Publicado: (2016)

Isolation of Circulating Plasma Cells in Multiple Myeloma Using CD138 Antibody-Based Capture in a Microfluidic Device
por: Qasaimeh, Mohammad A., et al.
Publicado: (2017)

Contents of Volume 138
Publicado: (2008)

Flow Cytometry Assessment of In Vitro Generated CD138(+) Human Plasma Cells
por: Itoua Maïga, Rayelle, et al.
Publicado: (2014)

MicroRNA-138 suppresses glioblastoma proliferation through downregulation of CD44
por: Yeh, Margaret, et al.
Publicado: (2021)

Glucocorticoid prevents CD138 expression in T cells of autoimmune MRL/lpr mice
por: Xie, Tianhong, et al.
Publicado: (2022)

The Intensity and Pattern of Syndecan-1 (CD138) Expression in Normal and Diseased Livers
por: Atique, Muhammad, et al.
Publicado: (2023)

P848: TINOSTAMUSTINE (EDO-S101), AN ALKYLATOR AND HISTONE DEACETYLASE INHIBITOR, ENHANCES THE EFFICACY OF DARATUMUMAB IN PRECLINICAL MODELS OF MULTIPLE MYELOMA
por: Diaz-Tejedor, A., et al.
Publicado: (2022)

A Multiepitope of XBP1, CD138 and CS1 Peptides Induces Myeloma-Specific Cytotoxic T lymphocytes in T cells of Smoldering Myeloma Patients
por: Bae, Jooeun, et al.
Publicado: (2014)

An approach for diagnosing plasma cell myeloma by three-color flow cytometry based on kappa/lambda ratios of CD38-gated CD138(+) cells
por: Nakayama, Shoko, et al.
Publicado: (2012)

CD138(-) multiple myeloma cells express high level of CHK1 which correlated to overall survival in MM patient
por: Wu, Dong, et al.
Publicado: (2020)

miRNA-seq identification and clinical validation of CD138+ and circulating miR-25 in treatment response of multiple myeloma
por: Papadimitriou, Maria-Alexandra, et al.
Publicado: (2023)

Correlation Between Baseline 18F-FDG PET/CT Findings and CD38- and CD138-Expressing Myeloma Cells in Bone Marrow and Clinical Parameters in Patients with Multiple Myeloma
por: Cengiz, Arzu, et al.
Publicado: (2018)

Study on expression of plasma sCD138 in patients with hemorrhagic fever with renal syndrome
por: Li, Jing, et al.
Publicado: (2018)

Expression Profile of Stemness Markers CD138, Nestin and Alpha-SMA in Ameloblastic Tumours
por: Yiannis, Callisthenis, et al.
Publicado: (2021)

Investigation of the Relationship between Chronic Endometritis Manifestations under Hysteroscope and CD138 Expression
por: Wang, Shuang, et al.
Publicado: (2022)

Low-Level Expression of CD138 Marks Naturally Arising Anergic B Cells
por: Lee, Sujin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_f37pia745t274hk4ktqq0n2s7j